Home / Stocks / Mankind Pharma Limited
MANKIND

Mankind Pharma Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹2,629.0

Change

+4.0 (0.15%)

Open

₹2,625.0

Prev. Close

₹2,625.0

Day High

₹2,637.8

Day Low

₹2,584.0

Volume Analysis

Traded

209,593

Delivered

109,862

Delivery %

52.42%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Trading within 3% of its 52-week high (₹2705.0)
  • •Strong operating margin (27.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year revenue growth (17.7%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹2,703.66 ₹2,670.73 ₹2,649.86 ₹2,616.93 ₹2,596.06 ₹2,563.13 ₹2,542.26
Fibonacci ₹2,670.73 ₹2,650.18 ₹2,637.48 ₹2,616.93 ₹2,596.38 ₹2,583.68 ₹2,563.13
Camarilla ₹2,643.8 ₹2,638.86 ₹2,633.93 ₹2,616.93 ₹2,624.07 ₹2,619.14 ₹2,614.21

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+21.45%

1 Week

-0.36%

1 Month

+15.03%

3 Months

+10.28%

6 Months

+6.03%

1 Year

+17.39%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹666.46

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

11.9%

Net margin 14.72% × asset turnover 0.49x × equity multiplier 1.65x

Company Overview

Sector

Healthcare

Market Cap

₹108,424 Cr

P/E (TTM)

46.5

ROE

13.1%

Book Value

₹426.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Mankind Pharma Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (99/100), while Valuation (11/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹2705.0); strong operating margin (27.0%); promoter holding is falling. Strong 3-year revenue growth (17.7%).

TopFund Score — Fundamentals Quality

70/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

99

Growth

71

Valuation

11

Cash Flow

75

Corporate Governance

46

Momentum

90

Institutional Ownership

68

Business Quality

76

Risk & Volatility

76

Liquidity

82

From Screener.in

  • +Company has reduced debt.
  • −Promoter holding has decreased over last 3 years: -3.88%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

KFin Technologies, Mankind Pharma's RTA, shifts corporate office from December 1, 2026.

Mankind Pharma will participate in the 2026 Jefferies Global Healthcare Conference in London from November 16-19, 2026.

SES assigned Mankind Pharma an ESG rating of 64.8 for FY26.

Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 2,708 2,607 2,422 2,868 3,061 3,199 3,079 3,570 3,697 3,567 3,443 4,031 4,338
Expenses + 2,025 2,000 1,836 2,196 2,214 2,383 2,396 2,724 2,776 2,648 2,513 2,974 3,167
Operating Profit 683 606 586 672 847 816 683 847 921 919 930 1,056 1,171
OPM % 25.0% 23.0% 24.0% 23.0% 28.0% 26.0% 22.0% 24.0% 25.0% 26.0% 27.0% 26.0% 27.0%
Other Income + 63 75 94 108 109 87 249 83 94 -31 94 49 99
Interest 9 9 9 11 7 221 191 171 170 157 142 110 105
Depreciation 96 110 100 103 100 187 231 219 222 223 223 226 236
Profit before tax 641 562 572 666 849 495 511 540 624 509 659 769 929
Tax % 20.0% 18.0% 17.0% 18.0% 22.0% 22.0% 17.0% 18.0% 17.0% 19.0% 15.0% 25.0% 23.0%
Net Profit + 511 460 477 543 659 385 425 445 520 414 559 574 716
EPS in Rs 13 11 12 13 16 9 10 11 12 10 13 14 17
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 12 25 18 11 13 23 27 24 21 12 12 13 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 3,334 5,865 6,214 7,782 8,749 10,260 12,207 14,278 15,379
Expenses + 2,748 4,427 4,565 5,791 6,848 7,743 9,182 10,653 11,302
Operating Profit 586 1,438 1,649 1,991 1,902 2,517 3,026 3,625 4,077
OPM % 18.0% 25.0% 27.0% 26.0% 22.0% 25.0% 25.0% 25.0% 27.0%
Other Income + 76 122 183 210 141 295 548 238 211
Interest 2 23 21 60 46 34 432 644 514
Depreciation 39 99 119 167 326 378 621 886 907
Profit before tax 621 1,438 1,692 1,975 1,671 2,399 2,521 2,333 2,867
Tax % 29.0% 27.0% 24.0% 26.0% 22.0% 19.0% 20.0% 17.0% —
Net Profit + 445 1,056 1,293 1,453 1,310 1,942 2,011 1,938 2,264
EPS in Rs 11 26 32 36 32 48 48 46 54
Dividend Payout % 0.0% 0.0% 24.0% 0.0% 0.0% 0.0% 0.0% 2.0% —
Sales growth — — 6 25 12 17 19 17 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 2,035 3,445 4,682 6,115 7,395 9,323 14,291 16,259 17,541
Borrowings + 0 131 241 873 170 207 8,511 6,312 5,422
Other Liabilities + 968 1,449 1,397 2,080 2,080 2,313 4,808 5,143 5,950
Total Liabilities 3,022 5,065 6,360 9,108 9,686 11,883 27,652 27,755 28,954
Fixed Assets + 316 1,600 1,664 3,588 4,251 4,545 19,005 18,620 18,854
CWIP 47 317 372 701 550 282 826 1,128 752
Investments 959 829 1,512 1,109 1,346 2,568 2,042 1,985 1,909
Other Assets + 1,700 2,319 2,811 3,709 3,538 4,488 5,780 6,022 7,439
Total Assets 3,022 5,065 6,360 9,108 9,686 11,883 27,652 27,755 28,954
Equity Capital 20 40 40 40 40 40 41 41 41

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + — 1,070 1,137 920 1,813 2,152 2,413 3,121
Cash from Investing Activity + — -436 -1,222 -1,369 -1,052 -2,081 -12,624 -181
Cash from Financing Activity + — -531 -8 605 -740 5 10,233 -2,953
Net Cash Flow — 103 -92 156 22 77 22 -12
Free Cash Flow — 853 826 -1,423 987 1,771 1,895 2,387
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit — 97 96 71 112 103 98 102

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 76.5% → 72.62%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 6.97% 4.1% 3.61% 2.86% 2.89% 2.89% 2.75% 2.57% 2.75% 2.63% 2.53% 2.46%
Promoters 76.5% 74.88% 74.87% 74.87% 72.71% 72.7% 72.67% 72.67% 72.66% 72.66% 72.63% 72.62%
FII 6.74% 9.87% 11.58% 12.37% 13.34% 12.92% 13.07% 12.83% 11.34% 10.24% 9.45% 9.37%
DII 9.78% 11.14% 9.94% 9.91% 11.05% 11.47% 11.5% 11.91% 13.26% 14.46% 15.39% 15.54%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Mankind Pharma Limited (this stock) 108,424 46.5 6.16 13.1%
Cipla Ltd 112,563 36.2 3.18 11.6%
Aurobindo Pharma Ltd 104,215 25.7 2.64 10.1%
Dr. Reddy S Laboratories 115,092 41.1 2.96 11.2%
Max Healthcare Ins Ltd 99,557 70.1 8.82 14.7%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%
Laurus Labs Limited 125,380 93.6 20.73 18.3%

Which Mutual Funds Hold Mankind Pharma Limited?

Frequently Asked Questions about Mankind Pharma Limited

Community Sentiment

What are other investors saying about Mankind Pharma Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.